Esaxerenone Use in Patients with Type 2 Diabetes and Chronic Kidney Disease: Clinical Evidence and Practical Considerations

Abstract

The management of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) remains a significant clinical challenge, with a persistent need for novel therapeutic approaches to mitigate progression and cardiovascular risk. Esaxerenone, a non-steroidal selective mineralocorticoid receptor antagonist (MRA), has emerged as a promising agent in this context. This review critically evaluates the scientific evidence supporting the use of esaxerenone in patients with T2DM and CKD, focusing on its mechanism of action, efficacy, safety, and place in contemporary treatment algorithms. The discussion integrates epidemiological data, pathophysiological rationale, clinical trial findings, and guideline recommendations to provide practical insights for clinicians managing this high-risk population.

Introduction

Type 2 diabetes mellitus is a leading cause of CKD worldwide, conferring substantial morbidity and mortality due to progressive renal impairment and heightened cardiovascular risk. Despite advances in glycemic and blood pressure control, residual risk persists, underscoring the need for therapeutic innovation. Mineralocorticoid receptor overactivation is increasingly recognized as a key driver of kidney and cardiovascular damage in diabetic CKD. Esaxerenone, a novel non-steroidal MRA, selectively antagonizes this pathway, offering potential nephro- and cardioprotection beyond conventional renin-angiotensin system (RAS) blockade. This review synthesizes current evidence on esaxerenone, emphasizing clinical applicability in T2DM with CKD.

Epidemiology / Disease Burden

The global prevalence of CKD among individuals with T2DM is estimated at 30-40%, representing millions at risk for end-stage renal disease (ESRD) and cardiovascular events. In Asia, where T2DM incidence is rapidly rising, the burden of diabetic CKD is particularly pronounced. CKD in T2DM is associated with increased hospitalizations, progression to dialysis, and substantial healthcare costs. Despite established use of RAS inhibitors and SGLT2 inhibitors, a significant proportion of patients continue to experience decline in renal function, emphasizing the need for adjunctive therapies.

Pathophysiology

Diabetic kidney disease is characterized by complex pathophysiological mechanisms including glomerular hyperfiltration, podocyte injury, inflammation, and fibrosis. Mineralocorticoid receptor (MR) overactivation in renal and cardiovascular tissues promotes sodium retention, oxidative stress, and profibrotic signaling, exacerbating albuminuria and renal injury. MR antagonism thus represents a targeted approach to disrupt these pathological processes. Esaxerenone provides potent, selective MR blockade, minimizing off-target effects observed with earlier steroidal MRAs such as spironolactone and eplerenone.

Risk Factors

Major risk factors for CKD progression in T2DM include poor glycemic control, hypertension, dyslipidemia, persistent albuminuria, smoking, obesity, and genetic predisposition. Chronic activation of the renin-angiotensin-aldosterone system (RAAS) and sustained mineralocorticoid signaling further potentiate renal and cardiovascular damage. Recognizing these risk factors is critical for identifying candidates who may benefit most from MR antagonism with agents such as esaxerenone.

Clinical Features

CKD in T2DM typically presents insidiously, with progressive albuminuria and declining estimated glomerular filtration rate (eGFR). Clinical features may include hypertension, edema, and proteinuria, with late-stage disease manifesting as uremic symptoms. Early detection through screening of urinary albumin and eGFR is essential for timely intervention. MR overactivation may contribute to refractory hypertension and persistent proteinuria despite standard therapy, highlighting the rationale for added MR blockade in specific phenotypes.

Diagnosis

Diagnosis of diabetic CKD relies on persistent reduction in eGFR (<60 mL/min/1.73m2) and/or elevated urinary albumin excretion (>30 mg/g creatinine) for at least three months, in a patient with established T2DM. Comprehensive assessment includes urinalysis, renal imaging, and exclusion of non-diabetic nephropathies. Quantitative measures of albuminuria and serial eGFR monitoring guide staging and inform prognosis. MRAs like esaxerenone are considered in patients with persistent albuminuria despite optimized RAS blockade.

Treatment & Management

Current management of CKD in T2DM centers on intensive glycemic and blood pressure control, RAS inhibition, SGLT2 inhibitors, and lifestyle modification. Despite these measures, many patients exhibit ongoing albuminuria and progressive renal decline. Esaxerenone has demonstrated significant reductions in albuminuria and stabilization of eGFR when added to standard therapy. Its non-steroidal nature confers a favorable safety profile, particularly regarding hyperkalemia risk, when compared to traditional MRAs. Dose titration and monitoring of serum potassium and renal function are essential to optimize benefits and minimize adverse effects.

Recent Advances / Emerging Therapies

Recent randomized controlled trials, such as the ESAX-DN and PLANET trials, have validated the efficacy of esaxerenone in reducing urinary albumin excretion and attenuating renal function decline in patients with T2DM and CKD. These studies have shown that esaxerenone, when used in conjunction with RAS inhibitors, leads to greater reductions in albuminuria without a proportionate increase in severe hyperkalemia. Emerging data also suggest potential cardiovascular benefits, including reductions in blood pressure and left ventricular hypertrophy. Ongoing research is exploring long-term renal outcomes, cardiovascular event reduction, and applicability in broader CKD populations.

Guideline Recommendations

Contemporary guidelines from organizations such as KDIGO and the Japanese Society of Nephrology recognize the potential role of non-steroidal MRAs, including esaxerenone, as adjuncts in patients with T2DM and CKD who remain at high risk despite RAS and SGLT2 inhibition. Careful patient selection, regular monitoring for hyperkalemia, and individualized risk-benefit assessment are emphasized. Integration of esaxerenone into treatment algorithms is evolving rapidly as new evidence emerges, underscoring the importance of staying abreast of guideline updates.

Conclusion

Esaxerenone represents a scientifically validated, mechanistically targeted therapy for patients with T2DM and CKD, offering incremental benefits in albuminuria reduction and renal protection when added to standard care. Its favorable efficacy and safety profile, supported by recent clinical trials and emerging guideline endorsements, position esaxerenone as an important option for nephroprotection in this high-risk population. Ongoing studies will further clarify its long-term impact on renal and cardiovascular outcomes and refine its optimal use in clinical practice.